ClinicalTrials.gg
RecruitingNCT07712939Updated Oct 21, 2026

A Phase 1, First-in-Human Study of CND319 in Healthy Participants and Patients With Rheumatic Diseases

A Phase 1 interventional study of CND319 in Healthy Participants Study, Rheumatoid Arthritis and Sjogren's Syndrome, sponsored by Candid Therapeutics. Recruiting at 1 site in Australia. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-21.

Primary conditionSjogren's SyndromeRegistry: Arthritis, RheumatoidReclassifiedWhy we changed it
Registry
Arthritis, Rheumatoid — the first condition term the registry derived for this study.
ClinicalTrials.gg
Sjogren's Syndrome
Why
  1. The study's listed conditions name Sjogren's Syndrome, a narrower term within Arthritis, Rheumatoid.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Candid Therapeutics (part of UCB S.A.) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2026; still recruiting 3 months later.
Updated Oct 21, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
105
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 18 studies in Sjogren's Syndrome with a site in Australia — 7 open to participants now, 11 under way, 6 of them phase 3. Sjogren's Syndrome · Australia.

Planned enrollment
11th of 18
105 · median 240
Started
2026
with 4 others
Phase 1
3 of 18
3 open now
Primary completion
2028-03
later than 4 of 10 live
Registered
17th of 18
by date
Lead sponsor
1 of 18
Candid Therapeutics

Among the 18 studies in Sjogren's Syndrome with a site in Australia, this one is the 11th largest by planned enrollment, is one of 5 that started in 2026, is one of 3 in phase 1, reaches primary completion later than 4 of the 10 other live ones, and was the 17th registered.

Sjogren's Syndrome

330 studies on the registry are indexed under Sjogren's Syndrome; 99 are open to participants now.

Browse Sjogren's Syndrome studies →

Open to participants now

7 of the 18 studies in Sjogren's Syndrome with a site in Australia are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 67 Sjogren's Syndrome studies recruiting now, 26 (39%) set no upper age limit and 25 (37%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Sjogren's Syndrome with a site in Australia, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary clinical activity of CND319 in healthy adult participants and patients with rheumatic diseases.

Read the detailed description

This is a Phase 1, first-in-human, single and multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary clinical activity of CND319 in healthy participants and patients with rheumatic diseases. The study consists of two parts: a dose escalation part and an open-label expansion.

03

Conditions studied

  • Healthy Participants Study
  • Rheumatoid Arthritis
  • Sjogren's Syndrome

Browse trials for

04

In context

Sjogren's Syndrome Reclassified

330 studies on the registry are indexed under Sjogren's Syndrome; 99 are open to participants now.

This study's planned enrollment of 105 is above the median of 50 across 218 interventional studies indexed under Sjogren's Syndrome.

Browse Sjogren's Syndrome studies →

Lead sponsor

Candid Therapeutics is the lead sponsor of 7 studies on the registry; 4 are open to participants now.

First submitted after Candid Therapeutics became part of UCB S.A..

Compared within Sjogren's Syndrome, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Arthritis, Rheumatoid. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria (SAD):

  1. 18 to 65 years old
  2. 18-30 kg/m2 and weight 55-100 kg
  3. Individuals in good health
  4. Agree to abstain from consumption of alcohol 48 hours prior to study visits
  5. Agree to the use of highly effective as defined in the protocol

Inclusion Criteria (MAD and Part 2 Expansion):

Patients with RA:

  1. 18 to 75 years old
  2. Diagnosis of adult-onset RA
  3. Class I-III RA
  4. Moderately to severely active RA

Patients with SjD:

  1. 18 to 75 years old
  2. Diagnosis of primary SjD

Exclusion Criteria (SAD):

  1. Inadequate clinical laboratory parameters at Screening
  2. Active infection
  3. Receipt of or inability to discontinue any excluded therapies
  4. Individuals with immediate household contact with your children (eg, ≤ 6 years old) or persons
  5. History of alcohol or drug abuse within last 12 months
  6. Positive alcohol breathalyzer or drug screen prior to dosing
  7. Inability to comply with protocol-mandated requirements
  8. History of severe allergic or anaphylactic reactions to mAb therapy (or recombinant anti-body-related fusion proteins) or any constituents of study drug
  9. Major surgery requiring use of general anesthesia within 12 weeks or planned or expected major surgery during the study
  10. Blood donation or significant blood loss within 30 days
  11. Individuals considered to be part of a vulnerable population (eg, incarceration)
  12. Individuals that in the opinion of the Investigator, are not suitable for participation in the trial

Exclusion Criteria for patients with RA or SjD:

  1. Inadequate clinical laboratory parameters at Screening
  2. Active infection
  3. Receipt of or inability to discontinue any excluded therapies
  4. History of progressive multifocal leukoencephalopathy
  5. Central nervous system disease
  6. Presence of 1 or more significant concurrent medical conditions
  7. Have a diagnosis or history of malignant disease within 5 years
  8. History of severe allergic or anaphylactic reactions to mAb therapy (or recombinant antibody-related fusion proteins) or any constituents of study drug
  9. Women who are pregnant or breastfeeding
  10. Patients who do not agree to the use of highly effective contraception as defined by the protocol
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
105 participants (estimated)

Study arms

  • Experimental
    CND319

    CND319 will be dosed according to the assigned cohort

    Biological: CND319

Interventions

  • BiologicalCND319

    CND319

07

What researchers measure

Primary outcomes

  1. Incidence proportion and severity of treatment-emergent adverse events through end of study

    Time frame: Baseline through Week 12 (SAD) or Week 24 (MAD/Part 2)

  2. Changes to body temperature

    oral, tympanic, or axillary

    Time frame: Baseline through Week 12 (SAD) or Week 24 (MAD/Part 2)

  3. Changes to heart rate

    Time frame: Baseline through Week 12 (SAD) or Week 24 (MAD/Part 2)

  4. Changes to respiratory rate

    Time frame: Baseline through Week 12 (SAD) or Week 24 (MAD/Part 2)

  5. Changes to blood pressure

    systolic and diastolic

    Time frame: Baseline through Week 12 (SAD) or Week 24 (MAD/Part 2)

  6. Changes to pulse oximetry

    Time frame: Baseline through Week 12 (SAD) or Week 24 (MAD/Part 2)

  7. Changes from baseline in ECG parameters through end of study: PR interval

    Time frame: Baseline through Week 12 (SAD) or Week 24 (MAD/Part 2)

  8. Changes from baseline in ECG parameters through end of study: QRS interval

    Time frame: Baseline through Week 12 (SAD) or Week 24 (MAD/Part 2)

  9. Changes from baseline in ECG parameters through end of study: QT interval

    Time frame: Baseline through Week 12 (SAD) or Week 24 (MAD/Part 2)

  10. Changes from baseline in safety laboratory assessments through end of study

    Time frame: Baseline through Week 12 (SAD) or Week 24 (MAD/Part 2)

Secondary outcomes

  1. PK parameters for CND319: Maximum observed concentration (Cmax)

    Time frame: Baseline through Week 12 (SAD) or Week 24 (MAD/Part 2)

  2. PK parameters for CND319: Time to maximum observed concentration (Tmax)

    Time frame: Baseline through Week 12 (SAD) or Week 24 (MAD/Part 2)

  3. PK parameters for CND319: Area under the concentration-time curve (AUC)

    Time frame: Baseline through Week 12 (SAD) or Week 24 (MAD/Part 2)

  4. PK parameters for CND319: Apparent clearance (CL/F)

    Time frame: Baseline through Week 12 (SAD) or Week 24 (MAD/Part 2)

  5. PK parameters for CND319: Apparent volume of distribution (Vz/F)

    Time frame: Baseline through Week 12 (SAD) or Week 24 (MAD/Part 2)

  6. PK parameters for CND319: Terminal elimination half-life (t1/2)

    Time frame: Baseline through Week 12 (SAD) or Week 24 (MAD/Part 2)

  7. Frequency of participants/patients with anti-drug antibodies (ADAs)

    Time frame: Baseline through Week 12 (SAD) or Week 24 (MAD/Part 2)

  8. Percentage of participants/patients with anti-drug antibodies (ADAs)

    Time frame: Baseline through Week 12 (SAD) or Week 24 (MAD/Part 2)

08

Study locations

1 of 1 sites recruiting
  • Candid Clinical Site
    Melbourne, Victoria, Australia
    Recruiting
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2026 (actual). Primary completion is estimated for Mar 2028, 20 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2026
First posted
Jul 20, 2026
StartActual
Jul 22, 2026
Primary completionEst.
Mar 31, 2028
CompletionEst.
Mar 31, 2028
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Jul 20, 2026→Jul 22, 2026 (actual)
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    Start date Jul 20, 2026→Jul 22, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT07712939
Responsible party
Sponsor
First posted
Jul 20, 2026
Start date
Jul 22, 2026
Primary completion
Mar 31, 2028 (estimated)
Completion
Mar 31, 2028 (estimated)
Last update
Oct 21, 2026

Study contacts

Clinical Operations
Contact
ClinicalTrials@candidrx.com
8582470550

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion